A Chat with Anat

In this episode, I am joined by my fellow Vision Academy member Professor Sobha Sivaprasad, Professor of Retinal Clinical Studies at the UCL Institute of Ophthalmology and Consultant Ophthalmologist at Moorfields Eye Hospital in the United Kingdom. 
Join us as we discuss key aspects of the diagnosis and treatment of central serous chorioretinopathy (CSC). In this episode, we summarize published evidence for the treatment of CSC, and use the guidance developed by the Vision Academy to discuss practical disease management and treatment of phenotypic variations. We also dive into cases we have treated in our own clinics, and explore how access to treatment can vary between clinics and countries. 
To learn more about the diagnosis and treatment of CSC, read the Vision Academy Viewpoint and publication. For more information about patient-focused care, visit the nAMD Barometer and DR Barometer websites. 
If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode!  
Speaker disclosures: 
Professor Anat Loewenstein 
Consultant: 4DMT, Abbvie, Astellas, Aviceda, Bayer, Beyeonics, Boehringer Ingelheim; Eyepoint, NotalVision, Ocular Therapeutix, Oculis, Ocuphire, Opthea, Roche, and Voiant. 
Professor Sobha Sivaprasad 
Received funding/fees from AbbVie, Alimera Sciences, Amgen, Apellis, Astellas, Bayer, Biogen, Boehringer Ingelheim, Clearside Biomedical, EyeBio, EyePoint, Iveric Bio, Janssen, Kriya Therapeutics, Novo Nordisk, Ocular Therapeutix, OcuTerra, Optos, Ripple Therapeutics, Roche, Sanofi and Stealth BioTherapeutics, and is Editor in Chief of Eye.  
January 2026 | PP-PF-OPHT-ALL-0262-1
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.

The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

In this special episode filmed in Paris at EURETINA 2025, I am joined by a very special guest, my fellow Vision Academy and Barometer Program member Prof. Adrian Koh, who is founding partner and senior consultant at the Eye & Retina Surgeons, Camden Medical Centre, Singapore, and Director of Retinal Centre International.
Tune in as we dive into the current understanding of the well-being of healthcare professionals (HCPs) working in ophthalmology, and introduce the HCP Barometer Survey, the first comprehensive and holistic analysis of the complexities of HCP well-being in ophthalmology, from professional fulfilment to the impact of clinic capacity constraints.
If you are a practicing specialist, fellow, resident, postgraduate, nurse, or technician working in ophthalmology who regularly interacts with and provides care for patients, please click here to complete the survey and tell us about your experiences. 
If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode! 
Speaker disclosures:
Professor Anat Loewenstein
Consultant: 4DMT, AbbVie, Astellas, Aviceda, Bayer, Beyeonics, Boehringer Ingelheim; Eyepoint, NotalVision, Ocular Therapeutix, Oculis, Ocuphire, Opthea, Roche, and Voiant.
Professor Adrian Koh
Consultant: Allergan, Bayer, Carl Zeiss, Heidelberg, Novartis, Topcon.
October 2025 | PP-PF-OPHT-ALL-0247-1
Further information on topics discussed in this podcast:
Ansari AS, et al. Eur J Ophthalmol. 2023;33(4):1640–1649.
B Burgos-Blasco, et al. J Fr Ophtalmol. 2022;45(7):689–699.
Garrido-Hermosilla AM, et al. Int Ophthalmol. 2024;44(27).
Gould LF, et al. Can J  Ophthalmol. 2020;55(3):29–32. 
Grover R, et al. Ophthalmic Epidemiol. 2021;28:322–329.
Palakkamanil MM, et al. Can J Ophthalmol. 2022;57:e103–e106.
Patel AJ, et al. Ophthalmol Glaucoma. 2023;6:316–321.
Sedhom JA, et al. J Cataract Refract Surg. 2022;48(6):723–729.
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.

The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

In this special episode filmed in Paris at EURETINA 2025, I am joined by Professor Gemmy Cheung, Professor and Senior Consultant Ophthalmologist at the Singapore National Eye Centre, Duke-NUS Medical School, National University of Singapore, and my fellow Vision Academy and Barometer Program. 
Join us as we explore current guidance for the diagnosis and management of simultaneous geographic atrophy (GA) and choroidal/macular neovascularization (CNV/MNV) in clinical practice from the Vision Academy’s viewpoint. In this episode, Gemmy and I dive into insights from published literature on the clinical profile and pathophysiology of the disease and the recommendations from the Vision Academy for the diagnosis and management of simultaneous GA and CNV/MNV. Finally, we discuss the more sophisticated multimodal imaging we use in our clinics, including OCT-A and fundus autofluorescence. 
To learn more about clinical characteristics and underlying mechanisms of simultaneous GA and CNV/MNV, read the Vision Academy Viewpoint and publication on the incidence, characteristics, and treatments for simultaneous GA and CNV/MNV. For more information about patient-focused care, visit the nAMD Barometer and DR Barometer websites.
If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode! 
Speaker disclosures:
Professor Anat Loewenstein
Consultant: 4DMT, AbbVie, Astellas, Bayer, Beyeonics, Eyepoint, Notal Vision, Ocular Therapeutix, Ocuphire, Oculis, Opthea, Roche, Boehringer-Ingelheim, Aviceda, Voiant
Professor Gemmy Cheung
Consulting fees, speaker fees, and grants: Avirmax, Bayer, Boehringer Ingelheim, Iveric, Janssen, Iveric, Janssen, Novartis, Roche, Topcon, and Zeiss.
November 2025 | PP-PF-OPHT-ALL-0248-1
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.

The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

In this special episode, I am joined by two of my long-time friends and collaborators, Professor Jean-François Korobelnik, my Co-chair of the Vision Academy and Professor of Ophthalmology at the University Hospital of Bordeaux, France, and Dr Jane Barratt, my Co-chair of the Barometer Program, and former Secretary General and Global Advisor at the International Federation of Ageing.
Tune in as we unpack the statement “From the Community, For the Community,” exploring how collaborations between academia, industry, and non-governmental organizations shape clinical practice and influence policy, with practical advice for listeners keen to get involved in such initiatives, and drive meaningful change.
This episode was recorded live at the Joint Vision Academy Steering Committee and Barometer Leadership Coalition Meeting in Rome in February 2025. To learn more about these programs, find your country’s representative, and access the important materials and training resources for clinicians and patients to improve patient-focused care and clinical practice, visit the Vision Academy Program website and nAMD Barometer Program website.
If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode! 
Speaker disclosures:
Professor Anat Loewenstein
Consultant: 4DMT, Abbvie, Astellas, Aviceda, Bayer, Beyeonics, Boehringer Ingelheim; Eyepoint, NotalVision, Ocular Therapeutix, Oculis, Ocuphire, Opthea, Roche, and Voiant.
Professor Jean-François Korobelnik
Consultant: AbbVie, Adverum, Apellis, Bayer, Boehringer Ingelheim, Carl Zeiss Meditec, EyePoint, Ocular Therapeutix, Roche, SeaBeLife, and Théa; Member of data safety monitoring board: Alexion, Novo Nordisk, and Opthea.
Dr Jane Barratt
Consultant: Bayer.
August 2025 | PP-PF-OPHT-ALL-0231-1
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.

The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.

In this special episode, the roles have been reversed! Your host is Professor Tariq Aslam, Professor of Ophthalmology and Interface Technologies at the University of Manchester in the United Kingdom, who asked me questions sent in by my retinal community colleagues.
Tune in to hear how I balance my busy career with my well-being, the pep talks I give to nervous first-time patients and trainees, myths about retinal disease I’d like to erase forever, and even an embarrassing moment in my career! 
This episode was recorded live at the Joint Vision Academy Steering Committee and Barometer Leadership Coalition Meeting in Rome. To learn more about these programs and access the important materials and training resources for clinicians and patients to improve patient-focused care and clinical practice, visit the Vision Academy Program website and nAMD Barometer Program website.
If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode! 
Speaker disclosures:
Professor Anat Loewenstein
Consultant: 4DMT, Abbvie, Astellas, Aviceda, Bayer, Beyeonics, Boehringer Ingelheim; Eyepoint, NotalVision, Ocular Therapeutix, Oculis, Ocuphire, Opthea, Roche, and Voiant.
Professor Tariq Aslam
Grants, speaker fees, and travel: Bayer, Boehringer Ingelheim, Canon, Heidelberg, Novartis, Roche, Thea, and Topcon.
July 2025 PP-PF-OPHT-ALL-0230-1
This podcast series is intended for HCPs, and is not intended for UK audiences.
Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.
This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.

The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.
The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.